The Research Progress of Direct KRAS G12C Mutation Inhibitors

Abstract: KRAS mutations have long been considered undruggable. However, a series of direct KRAS mutation inhibitors have been developed since the switch II pocket was discovered recently. This review will summarize progress in the development of direct KRAS G12C mutation inhibitors, current relevan...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ai, Li, Min, Fang, Mingzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Society Journal Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262225/
https://www.ncbi.nlm.nih.gov/pubmed/34257597
http://dx.doi.org/10.3389/pore.2021.631095
Descripción
Sumario:Abstract: KRAS mutations have long been considered undruggable. However, a series of direct KRAS mutation inhibitors have been developed since the switch II pocket was discovered recently. This review will summarize progress in the development of direct KRAS G12C mutation inhibitors, current relevant drugs under study and challenges that need to be considered in future research.

Ejemplares similares